

Special Issue

Neuromodulation: Emerging Medical Therapies

Message from the Guest Editor

As an emerging class of medical therapies, neuromodulation uses implantable or non-implantable technology to change the activity of the central nervous system, peripheral nervous system or autonomic nervous system by means of electrical stimulation or drugs, so as to improve the symptoms of patients and improve their quality of life. Neuromodulation can be applied to many types of pain, epilepsy, Parkinson's disease, mental disease, angina pectoris, irritable bowel syndrome and diseases caused by peripheral neuropathy. The field of neuromodulation has significantly advanced in the past few decades in both hardware and software capabilities. Those advances led to improvements in patient outcomes and a reduction in adverse events and complications. The advancement of the technology is continuous and moving fast. This Special Issue is intended to discuss new innovations in neuromodulation including implantable devices, non-implantable devices, pulsed radiofrequency ablation and more.

Guest Editor

Dr. Alaa Abd-Elseyed

Department of Anesthesiology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53715, USA

Deadline for manuscript submissions

closed (30 September 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/169283

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).